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ABSTRACT
Macrophages are known to play an important role in the initiation and progression of atherosclerosis; however, the molecular signaling pathways in 
macrophages that are responsible for plaque rupture have not been fully identified. This study aims to identify biomarkers and therapy targets in macrophages 
in atherosclerotic conditions by systematic review. Research procedure of systematic reviews using the PRISMA protocol. The search engine used in this 
study is PubMed, with the keywords ([macrophage] AND atherosclerosis) AND (signaling pathway OR signaling pathway), the reference application used is 
Zotero to screen clinical articles. There were 689 articles identified and 11 clinical articles in inclusion criteria were obtained. The identification resulted in 30 
biomarkers associated with macrophages in atherosclerotic conditions. The proposed biomarkers of atherosclerosis are interleukin (IL)-1β and IL-18. The 
proposed potential therapy targets for atherosclerosis are LOX-1 and schematic images of biomarkers in atherosclerotic plaques.
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INTRODUCTION
The high incidence of cardiovascular disease is of course directly 
proportional to the risk factors that influence it. Atherosclerosis is 
known as a risk factor for cardiovascular disease [1-3]. Atherosclerosis 
conditions can lead to heart attacks [4] and strokes [5-7] where 
according to the WHO in 2019, four out of five deaths in the world are 
related to cardiovascular disease. Cardiovascular disease is the number 
1 cause of death globally, an estimated 17.9 million individuals died in 
2016, or 31% of the total causes of death globally [8,103].
Atherosclerosis is a chronic and progressive inflammatory disease 
characterized by the buildup of lipids and fibrous plaques in the 
intima lining of the arterial walls [9,10]. Macrophages are known 
to play an important role in the initiation and progression of 
atherosclerosis [11-15]. The formation of atherosclerosis is closely 
related to the function of macrophages in the body. The lesions in 
atherosclerosis contain a large number of immune cells, especially 
macrophages [16] and T cells [17-19]. The same thing was stated by 
Zhang [20] that monocytes and macrophages play an important role 
in the progression of atherosclerosis, but the mechanism is not fully 
known.
Macrophages are included in the main cells of the immune 
system [21-23]. In carrying out its function, macrophages can 
act as Antigen Presenting Cells (APC) cells and as effector cells 
[24,25]. As APCs, macrophages play a role in capturing antigens to 
present to lymphocytes while as effector cells macrophages play a 
role in phagocytosis and the killing of microbes or foreign bodies. 
Macrophages are blood monocytes that come out into the tissue and 
differentiate when there is an inflammatory process. Macrophages 
are found in all connective tissue and organs [104]. According to Dahl 
[26], macrophages are the center of local inflammatory processes and 
apoptosis that lead to instability and plaque rupture; however, the 
molecular signaling pathways in macrophages that are responsible for 
plaque rupture have not been fully identified. 
The early stages of atherosclerosis can occur in adolescence and develop 
slowly [27,28]. Clinical manifestations occur in the elderly and generally 
have a poor prognosis. Therefore, early detection of atherosclerosis is 
necessary as an effort to prevent and treat the cardiovascular disease 
early [29,30]. This study aims to identify biomarkers and therapeutic 
targets in macrophages in atherosclerotic conditions by conducting a 
systematic review, with the focus of the articles being studied in the 
form of clinical trial articles. 
The role of macrophages in the natural immune system, especially 
in conditions of atherosclerosis, is of course mediated by a series 
of molecular signaling pathways that are responsible for these 
conditions [31-33]. Thus, the importance of identifying biomarkers 
and therapeutic targets in macrophages in atherosclerotic conditions 
underlies the reasons for this study. By knowing the role of 
macrophages, it can be used as a reference in drug development with 
a targeted system or can be used as blood biomarkers to support the 
diagnosis of atherosclerosis conditions.
SEARCH STRATEGY AND LITERATURE MANAGEMENT
This systematic review research uses the PRISMA protocol starting 
with the search engine determination. The search engine used in this 
study is PubMed. Determining the search date to limit the addition 
of articles and determining the keywords used are very important 
in systematic review research to filter articles that are relevant to 
the research purpose. Identification was focused on selected clinical 
articles for further analysis. Initial identification is done by reading 
through the abstract of each article. The reference application used in 
this study is Zotero.
The keywords used in the PubMed search box are “macrophage and 
atherosclerosis” with the search date being set on September 20, 2019. 
Articles related to the keyword “macrophage and atherosclerosis” are still 
quite broad, so to narrow the scope and adjust to the research objectives, 
keywords are added. With the “signaling pathway.” Entering the PubMed 
search box is: ([macrophage] AND atherosclerosis) AND (signaling 
pathway OR signaling pathway). Then, the articles are grouped by type.
Downloaded journal articles are saved in the Zotero reference application. 
Then, to filter the scope of the signaling pathway again, in the Zotero search 
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box, enter the keyword “signaling pathway” in the all fields, and tags menu 
with the aim that the signaling pathway in question can be filtered from 
the entire article content. Initial identification was carried out by abstract 
screening of each study to differentiate between preclinical and clinical 
articles. Furthermore, data extraction of clinical articles that meet the 
criteria is carried out; biomarkers related to macrophages are grouped in 
atherosclerotic conditions, and further descriptive analysis.
The studies included in this systematic review study were clinical trial 
articles (original research) contained in PubMed with predetermined 
keywords and article search times, met inclusion criteria, and were free 
of exclusion criteria. Eligibility criteria include;
Inclusion criteria
Articles are original research, published in the PubMed search engine, 
using English, and clinical research.
Exclusion criteria
Articles other than original research (review, meta-analysis, and 
proceedings), preclinical research, and using languages other than 
English were not used as the subject of articles in this study.
Data on clinical articles that match the inclusion criteria were extracted 
manually and summarized into a table with data collected: research 
objectives, objects measured, methods used, patient demographics, and 
the results or conclusions obtained in each study.
The schematic of the article search process is shown in Fig. 1.
The data were analyzed descriptive and a schematic image of biomarkers 
was made on plaques containing macrophages in atherosclerotic 
conditions based on the results of the included clinical studies.
DATA SEARCH RESULTS
In accordance with the keywords written in the search engine box, 
the results obtained were 15,390 relevant articles. The 15,390 articles 
consist of journal articles: 15,113; reviews: 3258; systematic review: 3; 
clinical trial: 188; clinical study: 202; and 4 meta-analyzes.
The article related to the keyword “macrophage and atherosclerosis” is 
still quite extensive, so to narrow the scope and adjust to the research 
objectives, the keyword is added with “signaling pathway.” Entering 
the PubMed search box is: ([macrophage] AND atherosclerosis) AND 
(signaling pathway OR signaling pathway). The results obtained were 
1830 articles consisting of 1425 journal articles and 405 reviews.
1425 article journals are downloaded and stored on the Zotero 
reference app. Then, to filter the scope of the signaling pathway again, 
in the Zotero search box, enter the keyword “signaling pathway” in 
the all fields, and tags menu with the aim that the signaling pathway 
in question can be filtered from the entire article content. The results 
obtained were 689 articles with these keywords.
A total of 689 articles were identified based on the type of testing 
performed, namely, preclinical or clinical. Initial identification was 
carried out by the abstract screening of each study. The results obtained 
were 672 preclinical articles and 14 clinical articles. A total of three of 
the 14 clinical articles obtained were excluded from the study, with 
the reason that one article used cadaveric/corpse as the subject, and 
the other two articles did not use a model or sample of patients with 
atherosclerotic conditions so that a total of 11 clinical articles were 
subjected to further analysis. The schematic of the article search 
process and the results are shown in Fig. 2 and the summary table of 
the research objectives and key conclusions is shown in Table 1.
Based on the flow of the clinical article search process related to 
biomarkers in macrophages in atherosclerosis conditions, 11 clinical 
articles that met the criteria were obtained. Furthermore, biomarker 
identification was carried out for each article. Biomarkers obtained 
based on the identification were 30 biomarkers associated with 
macrophages in atherosclerotic conditions.
Biomarkers related to inflammatory pathways expressed in plaque 
were reported by six studies [20,34-38]. Plaque rupture was reported 
in two studies [39] and [40]. Biomarkers related to metabolic pathways 
were reported in five studies [20,34,39,41,42]. Types of biomarkers 
are grouped based on functional gene groups in the body, namely: 
Lipoproteins and metabolic pathways; adhesion, inflammation, and 
cell surface antigens; coagulation; gene-linked receptors (extracellular 
signaling); transport protein; and cell survival. Classification of marker 
types based on functional class related to the formation process 
of atherosclerosis along with the reference to the clinical articles 
included in detail are shown in Table 2 (all markers are upregulated in 
atherosclerosis except that marked *). Summary of biomarker values 
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Author, Reference Background/Research purpose Object Key conclusion
(Shi, 2015) [35] Evaluation of the expression of NLRP3 
inflammasome in atherosclerosis 
carotid plaque and plaque 
susceptibility
NLRP3 inflammasome •  There is an association between the NLRP3 
inflammasome and carotid atherosclerosis.
•  NLRP3, ASC, Caspase-1, IL-1ᵦ, IL-18: 
Association with plaque vulnerability and 
atherogenesis.
• IL-1ᵦ, IL-18 as predictors of atherosclerosis
(Watanabe, 2017) [37] •  CAD patients have increased 
reactivation of varicella-zoster virus 
infection and herpes zoster
•  The increase in age causes: 
memory loss of CD4 T cells with 
the virus, expression of PD-1 
immunoinhibitory receptors.
•  Macrophages in CAD patients increase 
ROS levels, causing a modification 
of the glycolytic enzyme pyruvate 
kinase M2 to result in increased IL1β 
and IL6 production (leading to cell 
disturbance)
•  Objective: To see pyruvate control 




•  Macrophages in CAD suppress T-cell 
activation: increase risk of infection by 
20-30%
•  Macrophages increase surface expression 
of immunoinhibitory ligands (PD-L1) or 
program death ligands, due to oversupply 
of glycolytic intermediate pyruvate 
in mitochondria macrophage CAD 
inducing (BMP4/p-SMAD1/5/IRF1) signaling 
pathway
•  Metabolite-based immunotherapy may be 
a potential strategy for restoring adaptive 
immunity in CAD patients
(Zhang, 2018) [20] •  Monocytes and macrophages play an 
important role in the progression of 
atherosclerosis, but their activities 
are not fully known
•  NAMPT is known to be present as 
a plaque component, but it is not 
known whether NAMPT is involved 
in the regulation of leukocytes in 
peripheral blood.
•  Purpose: To see the effect of NAMPT 
on the polarization of macrophages 
related to the NAMPT pathway in 
atherosclerosis.
Level NAMPT in ACS patients, 
IL-1ra, IL-10
•  The expression of NAMPT in PBMC and 
plasma of patients is higher than in normal 
patients
•  NAMPT/NAD+/Sirt1: up-regulation in 
ACS patients (due to increased e-NAMPT 
expression)
(Lee, 2013) [39] •  Resident macrophages have an 
important role in the rupture 
of atherosclerotic plaques, it is 
confirmed that there are genes 
expressed by macrophages.
•  Objectives: To see the differences 
in the characteristics of gene 
expression in ruptured and stable 
plaques
•  FABP-4 (Fatty acid-binding 
protein)
• Leptin
•  There are significant differences in gene 
expression produced in stable and ruptured 
plaques
•  There is increased expression of FABP4 and 
leptin in plaque
•  Down-regulation of PPAR/adipocytokine in 
plaque receiving potent therapy
(Kang, 2010) [42] •  FOS gene expression, important 
in the function of monocytes and 
macrophages. Can be inhibited by 
statins through disruption of the 
cholesterol signaling pathway
•  Purpose: to prove the hypothesis 
that blood FOS mRNA levels 
will be sensitive to statins in the 
treatment of low-density lipoprotein 
cholesterol levels.
FOS Expression in 
Blood as a low-density 
lipoprotein-Independent 
Marker of Statin Treatment
FOS: A transcription factor 
associated with the conversion 
of monocytes to macrophages
FOS: Associated with 
atherosclerosis
Localization of FOS in 
macrophages, smooth muscle 
cells in plaque has a role in the 
formation of atherosclerosis
•  Treatment with statins decreases FOS gene 
expression
•  FOS gene expression is sensitive to treatment 
with statins
(Li, 2015) [43] •  Statin therapy has an important role 
in stabilizing plaque in patients with 
unstable angina, but the mechanism 
has not been much explored.
•  Objective: Identification of 
microRNAs (miRNAs) to mediate 
the protective effect of statins in 
patients with unstable angina.
Effect of statin on circulating 
microRNAome and predicted 
function regulatory network in 
patients with unstable angina
•  Statins induce multiple miRNA expression 
in circulating patients with unstable angina, 
which indicates an important role in the 
regulation of the signaling pathway for 
pathogenesis of unstable angina (one of which 
is NGF signaling).
Table 1: Summary of the research objectives and key conclusions
(Contd...)
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Biomarkers expressed by atherosclerotic plaques included in 
a systematic review of clinical trials are presented in the form 
of a schematic image. The induction of chemotaxis is due to an 
inflammatory response that causes the transfer of monocytes in the 
blood to the tissues and turns into macrophages. Macrophages which 
are components of atherosclerotic plaques express several biomarkers, 
both in ruptured and non-ruptured plaques, are shown in Fig. 3
The results of clinical trial studies indicate a role for macrophages in 
atherosclerotic conditions. Supported by the expressed biomarkers 
atherosclerotic plaques containing macrophages were found in this study. 
The grouping of biomarkers in the study was adjusted to functional gene 
groups in the body, from the six functional gene groups the most biomarkers 
were obtained in the adhesion, inflammation, and cell surface antigen 
groups, namely, 14 biomarkers. This is closely related to atherosclerosis 
which is basically an inflammatory condition due to the accumulation of 
low-density lipoprotein cholesterol (particles on the artery walls [44,45].
All studies show mixed results regarding the biomarkers expressed by 
macrophages, it can be said that none of the studies in this systematic 
review have the same research results, but still support one another.
Studies [34] have shown that the presence of metabolic pathways 
(Acyl coenzyme A: cholesterol acyltransferase, Lysosomal acid lipase, 
and Caveolin-2) and inflammatory pathways (CD-40, TFPI, and VEGF 
receptor 165) are compatible with atherosclerotic conditions, which 
are a combination of metabolic processes and inflammation [46-48].
Macrophages are associated with effector function, including secretion 
of pro-inflammatory cytokines interleukin [IL]-1β and IL-180) [35], 
lipid uptake, cholesterol transport, and phagocytosis [49]. During the 
lipid uptake process, macrophages turn into foam cells or foam cells 
and eventually undergo apoptosis [50,51] which is in line with the study 
results [40] showing the presence of caspase-3 expression in ruptured 
plaques. Macrophage apoptosis is the end result of the formation of 
Author, Reference Background/Research purpose Object Key conclusion
(Ng, 2003) [34] •  Men are more at risk of coronary 
disease than women.
•  Purpose: To identify the effect of 
androgens related to the expression 
of macrophage donor genes in men 
and women
Evaluation of the influence of 
androgens on men and women 
atherosclerosis 
•  Androgens increase expression of 
gene-related atherosclerosis, in male 
macrophages
•  There are 6 genes associated with 
up-regulated atherosclerosis, namely: Acyl 
coenzymeA: cholesterol acyl transferase 
I, lysosomal acid lipase (LAL), caveolin-2, 
CD40, vascular endothelial growth factor-165 
receptors, and tissue factor pathway 
inhibitors
(Dorweiler, 2014) [40] Purpose: to analyze the expression 
of the marker signaling pathway 
for apoptosis and proapoptosis 
UPR (Unfolded Protein Response) in 
plaque rupture in the human carotid 
artery.
• Caspase-3 
•  UPR proapoptotic signaling pathway 
activation identified in plaque rupture that 
occurs in the human carotid artery.
(Dunaeva, 2009) [36] Objectives: evaluation of 
the expression of signaling 
Hedgehog (Hh) molecules and 
chemotactic activity of Sonic 
hedgehog (Shh) in monocytes of CAD 
patients with or without DM.
• Shh
• Receptor Ptc
•  Shh: induced monocyte chemotaxis, does not 
induce monocytes in CAD+DM patients
•  Shh inhibition is thought to be 
pro-atherogenic
•  Strong PTc receptors are expressed by 
macrophages on atherosclerotic plaques, Shh 
as induced chemotaxis with activating the 
signaling pathway
(Li, 2004) [38] •  Glucose in DM patients increases 
cardiovascular risk
•  Objective: to assess the regulation of 
LOX1 expression on MDM (human 
monocyte-derived macrophage) by 
high glucose and the role of LOX1 
on glucose which induces foam cell 
formation.
LOX1 Glucose induces macrophages by forming 
atherosclerotic foam cells, by increasing LOX1 
receptor expression
(Peltonen, 2009) [41] •  Aortic valve stenosis (US): regulates 
the pathobiological process that 
shows some hallmarks (signs) of 
atherosclerosis
•  Apelin and its receptor, APJ, are 
widely expressed in the heart.
•  Objective: To determine the role of 
the apelin-APJ signaling pathway in 
aortic stenosis
•  Aortic stenosis is the narrowing 
of the aortic valve opening. Aortic 
stenosis restricts blood flow from 
the left ventricle to the aorta and 
can also affect the pressure in the 
left atrium.
Apelin •  Aortic valve stenosis, characterized by 
inflammation, calcification, and angiogenesis, 
is highly significant in association with the 
up-regulation of the apelin-APJ receptor 
pathway being the basis for a potential drug 
target.
•  The endothelium, especially in the blood 
vessels, is the site for the expression of apelin 
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foam cells as an inflammatory response that is thought to accelerate the 
process of necrotic nucleation at a later stage [52,53].
At an advanced stage (advanced plaque), macrophages accumulate in 
the ruptured area. This results in macrophages thought to contribute to 
the thinning of the fibrous layer and destabilization of atherosclerotic 
plaque, a mechanism that is thought to be mediated by the secretion 
of matrix destabilizing matrix metalloproteinases (MMPs) [49,54,55]. 
However, in this study no information was obtained related to MMPs.
IL-1β AND IL-18 AS PREDICTORS OF ATHEROSCLEROSIS
Atherogenesis is a biological process that occurs on a molecular 
scale  [56,57] so that molecularly targeted atherosclerosis treatment 
is still being developed [17,58-64]. Based on this systematic review, 
biomarkers for the identification of atherosclerosis are proposed, 
namely IL-1β and IL-18 [35]. Based on statistical tests, it was reported 
that the plasma levels of IL-1β and IL-18 differed significantly in the 
conditions of atherosclerotic patients compared with controls. The 
Table 2: Classification of marker types based on functional class
Fungsional Gene Gene Name/Biomarkers Reference
Lipoprotein and metabolic pathway Acyl coenzyme A: cholesterol acyltransferase [34]
Lysosomal acid lipase [34]
Caveolin-2 [34]
NAMPT (Nicotinamide phosphoribosyltransferase) [20]
Leptin [39]
Heme oxygenase (decycling) 1 [39]
Dehydrogenase/reductase (SDR family) member 9 [39]
APELIN [41]
FOS [42]
Adhesi, inflammation and cell surface antigen CD 40 [34]
NLRP3 [35]
ASC (apoptosis-associated speck-like protein with a C-terminal 
caspase-recruitment domain)
[35]





PD-L1 (Program death ligan -1) [37]
Proapoptotic caspase adaptor protein [39]
Fc fragment of IgG, low affinity IIIa/b, receptor (FCGR3AB) [39]
CD38 antigen (p45) [39]
Immunoglobulin lambda joining 3 [39]
Shh* [36]
Coagulation Tissue factor pathway inhibitor [34]
Gene-linked receptors (extracellular signaling) Vascular endothelial cell growth factor 165 receptor [34]
PTc receptor [36]
LOX 1 [38]
Protein transport Fatty acid binding protein 4 (FABP4) [39]
Cell survival NGF* [43]
CASPASE 3 [40]
IL: Interleukin
Fig. 3. Biomarkers in atherosclerotic plaques
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sample used is carotid plaque taken from the patient’s surgery so that it 
can describe the components directly on the plaque. Besides, the results 
of data extraction from 11 clinical articles showed that only IL-1β and 
IL-18 were reported to be measured using ELISA (mostly using reverse 
transcription polymerase chain reaction and immunohistochemistry 
methods). The plasma IL-1β level is 30,000–35,000 pg/ml while the 
plasma IL-18 level is 300–350 ng/l so that these two biomarkers can be 
used as predictors of atherosclerosis conditions. 
Support data from preclinical research [65] that generated mice lacking 
both apoE and IL-1β. The sizes of atherosclerotic lesions at the aortic 
sinus in apoE−/−/IL-1β−/−mice at 12 and 24 weeks of age showed a 
significant decrease of approximately 30% compared with apoE−/−/
IL-1β+/+ mice, and the percentage of the atherosclerotic area to total 
area of apoE−/−/IL-1β−/− at 24 weeks of age also showed a significant 
decrease of about 30% compared with apoE−/−/IL-1β+/+. The mRNA 
levels of vascular cell adhesion molecule (VCAM)-1 and monocyte 
chemotactic protein-1 in the apoE−/−/IL-1β−/− aorta were significantly 
reduced compared with the apoE−/−/IL-1β+/+. Furthermore, VCAM-
1 was also reduced at the protein level in apoE−/−/IL-1β−/− aorta 
compared with apoE−/−/IL-1β+/+. The lack of IL-1β decreases the 
severity of atherosclerosis in apoE deficient mice, possibly through 
increased expressions of VCAM-1 and monocyte chemotactic protein-1 
in the aorta. 
The other study in vivo [66], XMA052 MG1K, a chimeric murine version 
of XOMA 052, inhibited the formation of atherosclerotic lesions in the 
ApoE−/− model at all three doses tested. This effect was comparable 
to that reported for complete genetic ablation of IL-1β or IL-1R1 on an 
ApoE−/− background and was associated with decreases in plasma non-
HDL/HDL cholesterol ratio and plaque lipid content and macrophage 
infiltration, demonstrate for the 1st time that an antibody targeting IL-
1β can inhibit the progression of atherosclerosis in vivo, highlighting 
the importance of this key cytokine in cardiovascular disease [67-78].
Study of IL-18 in preclinical [79] demonstrated that lack of endogenous 
IFN-γ ablated the effects of IL-18 on atherosclerosis, IL-18 in the 
atherogenic process[80-93] increases lesion development through 
enhancement of an inflammatory response involving an IFN-γ–
dependent mechanism [94,95].
LOX-1 AS A TARGET FOR ATHEROSCLEROSIS THERAPY
The proposed potential target therapy for the treatment of 
atherosclerotic conditions is LOX-1 which is a study conducted by 
Li et al. [38], supported by Xu et al. [96] who stated that LOX-1 is 
involved in endothelial dysfunction, monocyte adhesion, proliferation, 
migration, and apoptosis of smooth muscle cells, foam cell formation, 
platelet activation, and plaque instability; these are all very important 
in the pathogenesis of atherosclerosis [97-102]. This LOX-1-dependent 
biological process contributes to plaque instability and the final clinical 
sequela of life-threatening plaque rupture and tissue ischemia. LOX-1 
antagonists are thought to inhibit atherosclerosis by reducing these 
cellular events.
Over the past decade, many drugs including natural antioxidants, statins, 
anti-inflammatory agents, antihypertensive, and antihyperglycemic 
drugs have been shown to inhibit LOX-1 vascular expression and 
activity. Therefore, LOX-1 is an attractive therapeutic target to be 
developed in the atherosclerotic treatment in humans [96].
Thus, the complexity of atherosclerotic conditions is supported by 30 
biomarkers resulting from 11 clinical trials with macrophages as the 
main component of atherosclerotic plaque. All test results did not show 
the same results but were closely related to another.
CONCLUSIONS
The clinical studies included in this systematic review fit the criteria 
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atherosclerotic conditions, resulting in a total of 11 clinical trials. The 
identification resulted in 30 biomarkers which were presented in the 
form of a schematic image. The proposed biomarkers of atherosclerosis 
are IL-1β and IL-18, while the proposed potential targets for 
atherosclerosis therapy are LOX-1.
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